Myokardia reports positive results from clinical trial of MYK-491
Category: #health  By Pankaj Singh  Date: 2019-05-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Myokardia reports positive results from clinical trial of MYK-491

Myokardia, a clinical-stage biopharmaceutical company recently presented positive results from its phase 1a clinical trial of MYK-491 dose in healthy volunteers, at the European Society of Cardiology Heart Failure Congress, Greece. Innovated by Myokardia and Sanofi Pharmaceuticals, MYK-491 is an advanced activator molecule and is designed to increase contractility of heart, with minimal effects on myocardial relaxation, reports source.

First-in-human data from the clinical trial of MYK-491 in healthy volunteers has demonstrated the drug to be well tolerated. At higher drug concentrations, MYK -491 increased systolic function (contractility of heart) by 5% to 20% across various echocardiographic parameters with minimal impact on diastolic function.

June Lee, M.D., Executive VP and Chief Development Officer, Myokardia, was reportedly quoted saying that in developing MYK-491, the company targets heart muscle protein to increase contraction along with minimal impact on the heart’s ability to relax & fill itself with oxygenated blood between the beats.

Data from Phase 1a study of MYK-491 in healthy volunteers demonstrated desired effect and the results have been confirmed in Phase 1b study in patients with stable heart failure. The company is looking forward to assessing safety of the drug over several days in multiple-ascending dose study, he added.

As per sources close to the matter, the Phase 1 randomized study was designed to assess tolerability, safety, pharmacokinetics & pharmacodynamics of single-ascending oral doses of MYK-491.  In the study, 64 healthy adult volunteers enrolled to receive single-ascending doses of MYK-491, ranging from 3mg-550mg.

The drug dose was generally well tolerated and no dose-limiting toxicides were observed. The common adverse event reported was headache with no trends of increased adverse events frequency associated with higher concentrations of dose. Pharmacokinetic results indicated the drug may be agreeably received in the form of once- or twice-daily dosing.

           Presently, MYK-491 is being studied in a Phase 2a clinal trial for the treatment of patients with systolic heart failure, the case in which heart does not contract sufficiently to the meet demands of human body.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Amazon, NinjaCart in talks, retail firm to invest in fresh produce
Amazon, NinjaCart in talks, retail firm to invest in fresh produce
By Pankaj Singh

US-based tech giant looks enter one of the biggest untapped sectors

Amazon reportedly had meetings with Bengaluru-based fresh produce supply chain firm, NinjaCart, ...

Poshmark expands its retail business, ventures into home décor
Poshmark expands its retail business, ventures into home décor
By Pankaj Singh

The U.S.-based retail firm Poshmark has reportedly announced that it is expanding beyond its fashion market involving resale of clothes, bags, footwear and accessories to home decor.

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial

Adverum Biotechnologies doses first Wet AMD patient in phase-1 trial
By Pankaj Singh

The California-based Adverum Biotechnologies Inc., which caters to the unmet medical requirements in rare and ocular diseases, has announced that it dosed its first wet AMD patient in the second cohort of its OPTIC pha...